Cuu Long Pharmaceutical JSC Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Dec'23

Sep'23

Net Sales

3,40,016.73

5,10,263.16

2,35,615.34

2,82,978.66

2,77,940.29

3,89,058.39

2,59,341.73

Other Operating Income

0.00

Total Operating income

3,40,016.73

5,10,263.16

2,35,615.34

2,82,978.66

2,77,940.29

3,89,058.39

2,59,341.73

Raw Material Cost

2,61,103.28

4,45,482.86

2,01,400.39

2,44,217.01

2,15,600.53

3,08,628.45

2,25,479.35

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

28,557.48

33,495.51

30,180.81

27,294.87

29,490.49

0.00

30,797.28

Power Cost

0.00

Manufacturing Expenses

10,129.11

6,024.05

5,979.62

6,506.97

7,008.03

7,009.73

7,911.77

Selling and Distribution Expenses

35,553.09

42,575.23

34,798.16

33,761.53

29,131.52

45,891.24

33,862.92

Other Expenses

-3,868.66

-3,951.96

-3,616.04

-3,380.18

-3,649.85

-700.97

-3,870.90

Total Expenditure (Excl Depreciation)

2,96,656.37

4,88,058.10

2,36,198.55

2,77,978.54

2,44,732.05

3,54,519.68

2,59,342.28

Operating Profit (PBDIT) excl Other Income

43360.4

22205.100000000002

-583.2

5000.1

33208.200000000004

34538.7

-0.5

Other Income

944.05

7,945.31

8,881.53

15,784.54

1,853.88

8,755.45

8,878.55

Operating Profit (PBDIT)

56,447.28

39,704.62

17,833.18

30,359.65

44,655.51

52,929.29

18,523.53

Interest

10,129.11

6,024.05

5,979.62

6,506.97

7,008.03

7,009.73

7,911.77

Exceptional Items

0.00

Gross Profit (PBDT)

78,913.45

64,780.29

34,214.95

38,761.65

62,339.75

80,429.95

33,862.38

Depreciation

12,142.86

9,554.25

9,534.87

9,575.00

9,593.39

9,635.13

9,645.53

Profit Before Tax

34,175.31

24,126.33

2,318.70

14,277.69

28,054.09

36,284.42

966.23

Tax

9,018.51

5,054.98

755.23

3,053.32

5,767.77

7,337.63

268.46

Provisions and contingencies

0.00

Profit After Tax

25,012.71

18,924.62

1,414.36

11,091.46

22,140.67

28,852.24

575.53

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

25,012.71

18,924.62

1,414.36

11,091.46

22,140.67

28,852.24

575.53

Share in Profit of Associates

0.00

Minority Interest

144.09

146.73

149.11

132.91

145.65

94.55

122.23

Other related items

0.00

Consolidated Net Profit

25,156.79

19,071.35

1,563.46

11,224.37

22,286.32

28,946.79

697.77

Equity Capital

0.00

Face Value

10000.0

Reserves

15,09,189.85

14,84,177.14

14,64,996.75

14,63,582.39

14,61,690.94

14,32,350.27

14,03,506.44

Earnings per share (EPS)

342.45

259.1

19.36

151.85

303.13

395.01

7.88

Diluted Earnings per share

342.45

259.1

19.36

151.85

303.13

395.01

7.88

Operating Profit Margin (Excl OI)

12.75%

4.35%

-0.25%

1.77%

11.95%

8.88%

-0.0%

Gross Profit Margin

13.62%

6.6%

5.03%

8.43%

13.55%

11.8%

4.09%

PAT Margin

7.36%

3.71%

0.6%

3.92%

7.97%

7.42%

0.22%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Mar 2025 is 22.33% vs 17.38% in Mar 2024

Consolidate Net Profit

YoY Growth in quarter ended Mar 2025 is 12.88% vs 51.85% in Mar 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2025 is 29.68% vs 70.25% in Mar 2024

Interest

YoY Growth in quarter ended Mar 2025 is 44.54% vs -12.95% in Mar 2024

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2025 has improved from Mar 2024

Compare Quarterly Results Of Cuu Long Pharmaceutical JSC With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(VND)

Change(%)

Net Sales

3,40,016.73

5,15,308.58

-1,75,291.85

-34.02%

Other Operating Income

0.00

Total Operating income

3,40,016.73

5,15,308.58

-1,75,291.85

-34.02%

Raw Material Cost

2,61,103.28

4,12,261.46

-1,51,158.18

-36.67%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

28,557.48

2,32,832.78

-2,04,275.30

-87.73%

Power Cost

0.00

Manufacturing Expenses

10,129.11

18,418.89

-8,289.78

-45.01%

Selling and Distribution Expenses

35,553.09

66,444.22

-30,891.13

-46.49%

Other Expenses

-3,868.66

-25,125.17

21,256.51

84.60%

Total Expenditure (Excl Depreciation)

2,96,656.37

4,78,705.67

-1,82,049.30

-38.03%

Operating Profit (PBDIT) excl Other Income

43,360.36

36,602.91

6,757.45

18.46%

Other Income

944.05

35,979.94

-35,035.89

-97.38%

Operating Profit (PBDIT)

56,447.28

1,50,503.19

-94,055.91

-62.49%

Interest

10,129.11

18,418.89

-8,289.78

-45.01%

Exceptional Items

0.00

Gross Profit (PBDT)

78,913.45

1,03,047.13

-24,133.68

-23.42%

Depreciation

12,142.86

77,920.34

-65,777.48

-84.42%

Profit Before Tax

34,175.31

54,163.96

-19,988.65

-36.90%

Tax

9,018.51

16,702.47

-7,683.96

-46.00%

Provisions and contingencies

0.00

Profit After Tax

25,012.71

16,191.64

8,821.07

54.48%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

25,012.71

16,191.64

8,821.07

54.48%

Share in Profit of Associates

0.00

Minority Interest

144.09

21,269.85

-21,125.76

-99.32%

Other related items

0.00

Consolidated Net Profit

25,156.79

37,461.49

-12,304.70

-32.85%

Equity Capital

0.00

Face Value

10,000.00

0.00

Reserves

15,09,189.85

38,50,245.26

-23,41,055.41

-60.80%

Earnings per share (EPS)

342.45

47.63

294.82

618.98%

Diluted Earnings per share

342.45

47.63

294.82

618.98%

Operating Profit Margin (Excl OI)

12.75%

7.10%

0.00

5.65%

Gross Profit Margin

13.62%

25.63%

0.00

-12.01%

PAT Margin

7.36%

3.14%

0.00

4.22%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 34,001.67 Million

in Mar 2025

Figures in Million

QoQ Growth in quarter ended Mar 2025 is -33.36% vs 116.57% in Dec 2024

YoY Growth in quarter ended Mar 2025 is 22.33% vs 17.38% in Mar 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 2,515.68 Million

in Mar 2025

Figures in Million

QoQ Growth in quarter ended Mar 2025 is 31.91% vs 1,119.79% in Dec 2024

YoY Growth in quarter ended Mar 2025 is 12.88% vs 51.85% in Mar 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 5,550.32 Million

in Mar 2025

Figures in Million

QoQ Growth in quarter ended Mar 2025 is 74.76% vs 254.79% in Dec 2024

YoY Growth in quarter ended Mar 2025 is 29.68% vs 70.25% in Mar 2024

Quarterly - Interest

Interest 1,012.91 Million

in Mar 2025

Figures in Million

QoQ Growth in quarter ended Mar 2025 is 68.15% vs 0.74% in Dec 2024

YoY Growth in quarter ended Mar 2025 is 44.54% vs -12.95% in Mar 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 12.75%

in Mar 2025

Figures in %

QoQ Growth in quarter ended Mar 2025 has improved from Dec 2024

YoY Growth in quarter ended Mar 2025 has improved from Mar 2024